The increase in price target by Morgan Stanley suggests a positive outlook on Organogenesis Holdings, which could lead to a short-term increase in the stock price. The Equal-Weight rating indicates that the analyst believes the stock is fairly valued at its current price, but the raised target implies there may be some upside potential.